Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study

INTRODUCTION: Many individuals with type 2 diabetes (T2D) experience suboptimal glycemic control. Treatment intensification options include fixed-ratio combination products containing a basal insulin and a glucagon-like peptide-1 receptor agonist, such as iGlarLixi (insulin glargine 100 U/mL and lix...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuhisa, Munehide, Miyoshi, Hideaki, Yabe, Daisuke, Takahashi, Yoko, Morimoto, Yukiko, Terauchi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880089/
https://www.ncbi.nlm.nih.gov/pubmed/36422802
http://dx.doi.org/10.1007/s13300-022-01333-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880089/
https://www.ncbi.nlm.nih.gov/pubmed/36422802
http://dx.doi.org/10.1007/s13300-022-01333-w

Ejemplares similares